Innate Pharma S.A. ADS (IPHA)
IPHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1598599/000159859926000005/0001598599-26-000005-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IPHA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2019 |
| SEC CIK | 0001598599 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | I0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.1M |
| Net income | -$55.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -546.1% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.3× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-02-06 |
| Latest annual report | 20-F | 2026-04-01 |
| Latest quarterly / interim | 6-K | 2026-09-17 |
Source: SEC EDGAR submissions feed, 335 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CHRS | Coherus Oncology Inc. | $1.07 | +3.88% | $165.3M |
| DTIL | Precision BioSciences Inc. | $6.10 | -6.58% | $168.4M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
| STRO | Sutro Biopharma Inc. | $11.01 | -17.09% | $182.6M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
| CGEN | Compugen Ltd. | $1.98 | -4.35% | $187.3M |
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier